DNA vaccines encoding CEA and a CD40 ligand and methods of...

Details DNA vaccines encoding CEA and a CD40 ligand and methods of... DNA vaccines encoding CEA and a CD40 ligand and methods of...

2005-08-02

2005-08-02

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093210, C424S234100, C424S069000, C424S069000, C435S230000, C435S091100, C435S069100, C435S069300, C435S069500, C514S04400A, C536S023100, C536S023500

Reexamination Certificate

active

06923958

ABSTRACT:
A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.

REFERENCES:
patent: 5939400 (1999-08-01), Steinman et al.
patent: 6086891 (2000-07-01), Hurwitz et al.
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6207646 (2001-03-01), Kreig et al.
patent: 6214804 (2001-04-01), Felgner et al.
patent: 6235523 (2001-05-01), Gajewczyk et al.
patent: 2250428 (1997-05-01), None
patent: WO 99/43839 (1999-09-01), None
patent: WO 02/03961 (2002-01-01), None
Xiang et al. J. Immunol. 2001, vol. 167, pp. 4560-4565.
Rong Xiang, et al., Clinical Cancer Research, vol. 7, pp. 856s-864s (Mar. 2001) (Suppl.).
James W. Hodge, et al., Cancer Research, vol. 59, pp. 5800-5807 (Nov. 15, 1999).
Erik Kass, et al., Cancer Research, vol. 59, pp. 676-683 (Feb. 1, 1999).
Stephen D. Gillies, et al., Journal of Immunology, pp. 6195-6203 (1998).
Joanne P. McLaughlin, et al., Cancer Research, vol. 56, pp. 2361-2367 (May 15, 1996).
Shin Sasaki, et al., Nature Biotechnology, vol. 19, pp. 543-547 (Jun. 2001).
Nicholas P. Restifo, Nature Biotechnology, vol. 19, pp. 527-528 (Jun. 2001).
Wolfgang W. Leitner, et al., Cancer Research, vol. 60, pp. 51-55 (Jan. 1, 2000).
N.P. Restifo, et al., Gene Therapy, vol. 7, pp. 89-92, (2000).
Andreas G. Niethammer, et al., Nature Medicine, vol. 8 (12), pp. 1369-1375 (Dec., 2002).

Affiliated with

Also associated with

Rating

DNA vaccines encoding CEA and a CD40 ligand and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA vaccines encoding CEA and a CD40 ligand and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA vaccines encoding CEA and a CD40 ligand and methods of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3508527